Literature DB >> 25696347

A review of pulmonary arterial hypertension: Part 1. Novel insights and classification.

C T Gan, A Vonk Noordegraaf, K M J Marques, J G F Bronzwaer, P E Postmus, A Boonstra.   

Abstract

Pulmonary arterial hypertension (PAH) is a disease characterised by an increased pulmonary artery pressure. The precapillary pulmonary arteries show distinct pathobiological changes, i.e. medial hypertrophy, intimal fibrosis, microthrombi and plexiform lesions. Although the pathogenesis is not completely understood, pulmonary vascular proliferation and remodelling, due to a variety of mediators, is believed to play the pathogenetic key role. Genetic research reveals molecular deformities and gene mutations associated with phenotypic PAH. This article covers novel insights into pathobiology, pathogenesis and genes of PAH, which led to a novel classification system and a diagnostic work-up, emanated from the World Health Organisation Symposium on Pulmonary Hypertension in Venice in June 2003.

Entities:  

Keywords:  classification system; diagnostic work-up; genes; pathobiology; pathogenesis; pulmonary arterial hypertension

Year:  2004        PMID: 25696347      PMCID: PMC2497135     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  39 in total

Review 1.  Primary pulmonary hypertension: update on pathogenesis and novel therapies.

Authors:  A C Arroliga; R A Dweik; F J Kaneko; S C Erzurum
Journal:  Cleve Clin J Med       Date:  2000-03       Impact factor: 2.321

2.  Exercise pathophysiology in patients with primary pulmonary hypertension.

Authors:  X G Sun; J E Hansen; R J Oudiz; K Wasserman
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

3.  Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

Authors:  J H Newman; L Wheeler; K B Lane; E Loyd; R Gaddipati; J A Phillips; J E Loyd
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

Review 4.  Primary pulmonary hypertension.

Authors:  S P Gaine; L J Rubin
Journal:  Lancet       Date:  1998-08-29       Impact factor: 79.321

5.  Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

Authors:  O Sitbon; M Humbert; J L Jagot; O Taravella; M Fartoukh; F Parent; P Herve; G Simonneau
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

6.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

Review 7.  Primary pulmonary hypertension.

Authors:  James R Runo; James E Loyd
Journal:  Lancet       Date:  2003-05-03       Impact factor: 79.321

8.  Protective role of angiopoietin-1 in experimental pulmonary hypertension.

Authors:  Yidan D Zhao; Andrew I M Campbell; Malcolm Robb; Douglas Ng; Duncan J Stewart
Journal:  Circ Res       Date:  2003-04-10       Impact factor: 17.367

9.  MRI evaluation of right ventricular pressure overload in chronic obstructive pulmonary disease.

Authors:  J T Marcus; A Vonk Noordegraaf; P M De Vries; A C Van Rossum; B Roseboom; R M Heethaar; P E Postmus
Journal:  J Magn Reson Imaging       Date:  1998 Sep-Oct       Impact factor: 4.813

Review 10.  Role of pharmacologic tests in the treatment of primary pulmonary hypertension.

Authors:  N Galiè; G Ussia; P Passarelli; R Parlangeli; A Branzi; B Magnani
Journal:  Am J Cardiol       Date:  1995-01-19       Impact factor: 2.778

View more
  1 in total

1.  Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy.

Authors:  Maria F Acosta; Priya Muralidharan; Carissa L Grijalva; Michael D Abrahamson; Don Hayes; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 5.158

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.